KALA BIO, INC. Deferred Tax Assets, Tax Deferred Expense, Other
KALA BIO, INC. (KALA) had Deferred Tax Assets, Tax Deferred Expense, Other of $177.00 thousand as of 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2026-04-15
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $177.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $676.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $4.75M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $2.00M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other |
|---|---|
| 2025-12-31 | $177.00K 10-K · filed 2026-04-15 |
| 2024-12-31 | $676.00K 10-K · filed 2026-04-15 |
| 2023-12-31 | $4.75M 10-K · filed 2025-03-31 |
| 2022-12-31 | $2.00M 10-K · filed 2024-03-29 |
| 2021-12-31 | $1.26M 10-K · filed 2023-03-03 |
| 2020-12-31 | $2.61M 10-K · filed 2022-03-29 |
| 2019-12-31 | $2.47M 10-K · filed 2021-02-25 |
| 2018-12-31 | $1.32M 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |